Qlife Holding AB (publ) (QLIFE.ST)
SEK 2.1
(5.53%)
SEK 2.1
(5.53%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 244 Thousand SEK | -98.64% |
| 2022 | 17.99 Million SEK | -54.58% |
| 2021 | 39.61 Million SEK | 90.91% |
| 2020 | 20.75 Million SEK | 78.63% |
| 2019 | 11.61 Million SEK | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q2 | 39 Thousand SEK | 0.0% |
| 2024 Q1 | - SEK | -100.0% |
| 2023 FY | 244 Thousand SEK | -98.64% |
| 2023 Q3 | 45 Thousand SEK | -2.17% |
| 2023 Q4 | 30 Thousand SEK | -33.33% |
| 2023 Q1 | 123 Thousand SEK | -88.78% |
| 2023 Q2 | 46 Thousand SEK | -62.6% |
| 2022 Q3 | 1.96 Million SEK | -51.13% |
| 2022 Q2 | 4.02 Million SEK | -63.09% |
| 2022 Q1 | 10.9 Million SEK | -9.76% |
| 2022 FY | 17.99 Million SEK | -54.58% |
| 2022 Q4 | 1.09 Million SEK | -44.28% |
| 2021 Q1 | 11.17 Million SEK | 22.52% |
| 2021 FY | 39.61 Million SEK | 90.91% |
| 2021 Q4 | 12.08 Million SEK | 105.83% |
| 2021 Q3 | 5.87 Million SEK | -43.99% |
| 2021 Q2 | 10.48 Million SEK | -6.21% |
| 2020 FY | 20.75 Million SEK | 78.63% |
| 2020 Q4 | 9.12 Million SEK | 80.21% |
| 2020 Q3 | 5.06 Million SEK | -18.1% |
| 2020 Q2 | 6.18 Million SEK | 1505.45% |
| 2020 Q1 | 385 Thousand SEK | -89.13% |
| 2019 Q3 | 714 Thousand SEK | -67.82% |
| 2019 FY | 11.61 Million SEK | 0.0% |
| 2019 Q1 | 1.54 Million SEK | 0.0% |
| 2019 Q2 | 2.21 Million SEK | 44.0% |
| 2019 Q4 | 3.54 Million SEK | 396.22% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Acarix AB (publ) | 6.24 Million SEK | 96.09% |
| ADDvise Group AB (publ) | 1.37 Billion SEK | 99.982% |
| ADDvise Group AB (publ) | 1.37 Billion SEK | 99.982% |
| Arcoma AB | 163.01 Million SEK | 99.85% |
| Bactiguard Holding AB (publ) | 203.99 Million SEK | 99.88% |
| BICO Group AB (publ) | 2.23 Billion SEK | 99.989% |
| Boule Diagnostics AB (publ) | 571.32 Million SEK | 99.957% |
| CellaVision AB (publ) | 677.29 Million SEK | 99.964% |
| Clinical Laserthermia Systems AB (publ) | 8.27 Million SEK | 97.051% |
| Chordate Medical Holding AB (publ) | 976.28 Thousand SEK | 75.007% |
| C-Rad AB (publ) | 424.61 Million SEK | 99.943% |
| Duearity AB (publ) | 1.65 Million SEK | 85.248% |
| Dignitana AB (publ) | 86.06 Million SEK | 99.716% |
| Episurf Medical AB (publ) | 10.3 Million SEK | 97.631% |
| Getinge AB (publ) | 31.82 Billion SEK | 99.999% |
| Scandinavian Real Heart AB (Publ) | - SEK | -Infinity% |
| Iconovo AB (publ) | 7.07 Million SEK | 96.553% |
| Integrum AB (publ) | 104.11 Million SEK | 99.766% |
| Luxbright AB (publ) | 854.69 Thousand SEK | 71.452% |
| Mentice AB (publ) | 273.61 Million SEK | 99.911% |
| OssDsign AB (publ) | 112.15 Million SEK | 99.782% |
| Paxman AB (publ) | 210.11 Million SEK | 99.884% |
| Promimic AB (publ) | 37.07 Million SEK | 99.342% |
| SciBase Holding AB (publ) | 23.24 Million SEK | 98.95% |
| ScandiDos AB (publ) | 60.42 Million SEK | 99.596% |
| Sectra AB (publ) | 2.96 Billion SEK | 99.992% |
| Sedana Medical AB (publ) | 153.86 Million SEK | 99.841% |
| Senzime AB (publ) | 35.75 Million SEK | 99.318% |
| SpectraCure AB (publ) | 318 Thousand SEK | 23.27% |
| Stille AB | 294.89 Million SEK | 99.917% |
| Vitrolife AB (publ) | 3.51 Billion SEK | 99.993% |
| Xvivo Perfusion AB (publ) | 597.54 Million SEK | 99.959% |